We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

82 hedge funds and large institutions have $146M invested in Neos Therapeutics, Inc in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

168% more call options, than puts

Call options by funds: $4.74M | Put options by funds: $1.77M

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

65% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 17

30% more funds holding

Funds holding: 6382 (+19)

20% more capital invested

Capital invested by funds: $121M → $146M (+$24.2M)

Holders
82
Holders Change
+19
Holders Change %
+30.16%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
27
Increased
28
Reduced
17
Closed
8
Calls
$4.74M
Puts
$1.77M
Net Calls
+$2.97M
Net Calls Change
+$3.15M

NEOS Hedge Fund Activity: Q4 2017 in Review

82 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2017, worth a combined $146M — up 20% from $121M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new NEOS positions and 8 closed out — a net gain of 19 holders — while 28 added to existing stakes and 17 trimmed.

The largest buyer was Lyon Street Capital, adding an estimated $5.36M. The largest seller was Millennium Management, exiting entirely with an estimated $9.78M sold.

  • 82 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2017, up from 63 in Q3 2017.
  • Funds reported $146M of Neos Therapeutics, Inc stock for Q4 2017, up 20% quarter-over-quarter.
  • 27 funds opened new Neos Therapeutics, Inc positions in Q4 2017 and 8 closed out, a net change of +19 holders.
  • The largest Neos Therapeutics, Inc buyer in Q4 2017 was Lyon Street Capital, an estimated $5.36M added.
  • The largest Neos Therapeutics, Inc seller in Q4 2017 was Millennium Management, an estimated $9.78M sold.

Based on aggregated 13F filings for Q4 2017.